Carew JS - Search Results

1

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.

Nawrocki ST, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, Colombo A, Coffey M, Fernandez Hernandez E, Chen X, Nuovo GJ, Carew JS, Mohrbacher AF, Fields P, Kuhn P, Siddiqi I, Merchant A, Kelly KR. Nawrocki ST, et al. Among authors: carew js. Clin Cancer Res. 2023 Dec 15;29(24):5087-5103. doi: 10.1158/1078-0432.CCR-23-0229. Clin Cancer Res. 2023. PMID: 37812476 Free PMC article. Clinical Trial.

2

Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Carew JS, Nawrocki ST, Krupnik YV, Dunner K Jr, McConkey DJ, Keating MJ, Huang P. Carew JS, et al. Blood. 2006 Jan 1;107(1):222-31. doi: 10.1182/blood-2005-05-1923. Epub 2005 Sep 6. Blood. 2006. PMID: 16144803 Free PMC article.

3

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.

Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Among authors: carew js. Cancer Res. 2005 Dec 15;65(24):11510-9. doi: 10.1158/0008-5472.CAN-05-2394. Cancer Res. 2005. PMID: 16357160

4

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Among authors: carew js. Cancer Res. 2005 Dec 15;65(24):11658-66. doi: 10.1158/0008-5472.CAN-05-2370. Cancer Res. 2005. PMID: 16357177

5

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Among authors: carew js. Cancer Res. 2006 Apr 1;66(7):3773-81. doi: 10.1158/0008-5472.CAN-05-2961. Cancer Res. 2006. PMID: 16585204

6

Modulating autophagy for therapeutic benefit.

Carew JS, Nawrocki ST, Cleveland JL. Carew JS, et al. Autophagy. 2007 Sep-Oct;3(5):464-7. doi: 10.4161/auto.4311. Epub 2007 Apr 19. Autophagy. 2007. PMID: 17495516

7

Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.

Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Nawrocki ST, et al. Among authors: carew js. Cancer Res. 2007 Jul 15;67(14):6987-94. doi: 10.1158/0008-5472.CAN-07-0812. Cancer Res. 2007. PMID: 17638911

8

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

Carew JS, Giles FJ, Nawrocki ST. Carew JS, et al. Cancer Lett. 2008 Sep 28;269(1):7-17. doi: 10.1016/j.canlet.2008.03.037. Epub 2008 May 6. Cancer Lett. 2008. PMID: 18462867 Review.

9

The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.

Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA Jr, Marton LJ, Cleveland JL. Carew JS, et al. Cancer Res. 2008 Jun 15;68(12):4783-90. doi: 10.1158/0008-5472.CAN-07-6483. Cancer Res. 2008. PMID: 18559525 Free PMC article.

10

Targeting HSP90 for cancer therapy.

Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Mahalingam D, et al. Among authors: carew js. Br J Cancer. 2009 May 19;100(10):1523-9. doi: 10.1038/sj.bjc.6605066. Epub 2009 Apr 28. Br J Cancer. 2009. PMID: 19401686 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page